A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling

Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: Analysis of its long-term prognostic value

(2017) A. Tadlaoui Hbibi et al.   Cancer Biomarkers

The molecular pathology of cutaneous melanoma

(2017) Thomas Bogenrieder et al.   Cancer Biomarkers

Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032

(2015) Elisabetta Vergani et al.   NEOPLASIA

MEK'ing the Most of p53 Reactivation Therapy in Melanoma

(2012) John T. Lee et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

6-Bromoindirubin-3'-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells

(2011) L. Liu et al.   CANCER RESEARCH

Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options

(2011) J. Villanueva et al.   CANCER RESEARCH

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail

(2010) Gajanan S. Inamdar et al.   BIOCHEMICAL PHARMACOLOGY

5,5′-Substituted Indirubin-3′-oxime Derivatives as Potent Cyclin-Dependent Kinase Inhibitors with Anticancer Activity

(2010) Soo-Jeong Choi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The PKB/AKT Pathway in Cancer

(2009) Amancio Carnero   CURRENT PHARMACEUTICAL DESIGN

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Melanoma Drug Vindicates Targeted Approach

(2009) K. Garber   SCIENCE

mTORC1 promotes survival through translational control of Mcl-1

(2008) J. R. Mills et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA